glp-1 drugs addiction IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1 meds show promise for
Description
Still, affordability remains a major barrier
As we summarise in this concise review, preliminary evidence suggests that the cardioprotective benefits of GLP-1 RAs may also extend to HF
When losing weight, our bodies naturally adapt
Some early studies even found that some people using these drugs drank less alcohol or used fewer opioids
Prioritize protein, vegetables, and whole foods
Manufacturer The marketing authorisation holder is Novo Nordisk A/S, based in Denmark
